Connect Biopharma Holdings Limited
21.20%
13,160,000
1835268
Mar 30, 2026
Apr 1, 2026, 04:30 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Panacea Innovation Limited | CO | 21.20% | 13,160,000 | 0 | 13,160,000 |
| Panacea Venture Healthcare Fund II, L.P. | Partnership | 21.20% | 13,160,000 | 0 | 13,160,000 |
| Panacea Venture Healthcare Fund II GP Company, Ltd. | CO | 21.20% | 13,160,000 | 0 | 13,160,000 |
| James Huang | Individual | 21.20% | 13,160,000 | 0 | 13,160,000 |
Disclosure Items (6)
Ordinary Shares
Connect Biopharma Holdings Limited
3580 Carmel Mountain Road, San Diego, CA, 92130
Item 3 of the Schedule 13D is hereby amended and supplemented as follows: On March 31, 2026, in connection with the closing of the Offering (as defined below), Panacea Venture Healthcare Fund II, L.P. purchased 1,160,000 Ordinary Shares at a price of $3.45 per Ordinary Share. Panacea Venture Healthcare Fund II, L.P. obtained the funds used to purchase the Ordinary Shares through capital contributions from its partners.
Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The information contained on the cover pages to this Schedule 13D is incorporated by reference into this Item 5. The ownership information presented herein represents beneficial ownership of Ordinary Shares as of the date of this filing, based upon (1) 55,903,513 Ordinary Shares outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 12, 2025 and (2) 6,130,000 Ordinary Shares issued by the Issuer in connection with the Offering, as disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2026. Panacea Venture Healthcare Fund II, L.P. is the record holder of the Ordinary Shares reported herein. James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund II, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the Ordinary Shares directly reported herein, but each disclaims such beneficial ownership.
The information contained on the cover pages to this Schedule 13D is incorporated by reference into this Item 5.
Except as described in this Amendment No. 5, the Reporting Persons have not effected any transactions in the Ordinary Shares during the past sixty days.
None.
Not applicable.
Item 6 of the Schedule 13D is hereby amended and supplemented as follows: Item 4 above summarizes certain provisions of the Securities Purchase Agreement and is incorporated herein by reference. A copy of such agreement is attached as an exhibit to this Schedule 13D and is incorporated herein by reference. Except as set forth herein, none of the Reporting Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.
Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 2: Securities Purchase Agreement, dated March 29, 2026, by and between Connect Biopharma Holdings Limited and each of the purchasers party thereto (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2026).